Robert A.  Michael net worth and biography

Robert Michael Biography and Net Worth

Vice Chairman of AbbVie
Rob Michael is Vice Chairman, Finance and Commercial Operations and Chief Financial Officer, responsible for global commercial and financial operations of the company. He previously served as Executive Vice President, Chief Financial Officer.

Mr. Michael joined Abbott as a member of the Financial Development Program, and ultimately served as Division Controller, Nutrition Supply Chain and Division Controller, Abbott Molecular, among other roles.  After AbbVie’s separation from Abbott, Mr. Michael held a series of leadership roles of increasing responsibility including Vice President, Controller; Vice President, Treasurer; Vice President, Controller for Commercial Operations; and Vice President, AbbVie Financial Planning and Analysis.

He earned a bachelor’s degree in accounting from Indiana University Kelley School of Business and a master of business administration from University of California Los Angeles Anderson School of Management. He is also a Certified Public Accountant.

What is Robert A. Michael's net worth?

The estimated net worth of Robert A. Michael is at least $16.63 million as of February 29th, 2024. Mr. Michael owns 98,645 shares of AbbVie stock worth more than $16,630,561 as of June 15th. This net worth estimate does not reflect any other investments that Mr. Michael may own. Additionally, Mr. Michael receives a salary of $4,620,000.00 as Vice Chairman at AbbVie. Learn More about Robert A. Michael's net worth.

How old is Robert A. Michael?

Mr. Michael is currently 54 years old. There are 7 older executives and no younger executives at AbbVie. The oldest executive at AbbVie is Mr. Richard A. Gonzalez, Chairman & CEO, who is 70 years old. Learn More on Robert A. Michael's age.

What is Robert A. Michael's salary?

As the Vice Chairman of AbbVie Inc., Mr. Michael earns $4,620,000.00 per year. The highest earning executive at AbbVie is Mr. Richard A. Gonzalez, Chairman & CEO, who commands a salary of $7,190,000.00 per year. Learn More on Robert A. Michael's salary.

How do I contact Robert A. Michael?

The corporate mailing address for Mr. Michael and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Robert A. Michael's contact information.

Has Robert A. Michael been buying or selling shares of AbbVie?

Robert A. Michael has not been actively trading shares of AbbVie in the last ninety days. Most recently, Robert A. Michael sold 68,879 shares of the business's stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $176.45, for a transaction totalling $12,153,699.55. Following the completion of the sale, the chief operating officer now directly owns 98,645 shares of the company's stock, valued at $17,405,910.25. Learn More on Robert A. Michael's trading history.

Who are AbbVie's active insiders?

AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Kevin Buckbee (SVP), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Scott Reents (CFO), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Perry Siatis (EVP), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.

Are insiders buying or selling shares of AbbVie?

During the last year, insiders at the sold shares 11 times. They sold a total of 404,736 shares worth more than $70,989,822.24. The most recent insider tranaction occured on March, 20th when EVP Nicholas Donoghoe sold 21,082 shares worth more than $3,716,756.60. Insiders at AbbVie own 0.3% of the company. Learn More about insider trades at AbbVie.

Information on this page was last updated on 3/20/2024.

Robert A. Michael Insider Trading History at AbbVie

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/29/2024Sell68,879$176.45$12,153,699.5598,645View SEC Filing Icon  
3/1/2022Sell43,105$148.25$6,390,316.25View SEC Filing Icon  
2/28/2018Sell4,294$119.43$512,832.4211,170View SEC Filing Icon  
2/20/2018Sell992$120.31$119,347.52View SEC Filing Icon  
9/28/2017Sell6,699$88.00$589,512.0010,007View SEC Filing Icon  
3/10/2017Sell5,132$65.29$335,068.2816,706View SEC Filing Icon  
See Full Table

Robert A. Michael Buying and Selling Activity at AbbVie

This chart shows Robert A Michael's buying and selling at AbbVie by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AbbVie Company Overview

AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $168.59
Low: $166.00
High: $169.24

50 Day Range

MA: $163.56
Low: $154.86
High: $170.43

2 Week Range

Now: $168.59
Low: $130.96
High: $182.89

Volume

3,933,662 shs

Average Volume

5,477,690 shs

Market Capitalization

$297.71 billion

P/E Ratio

50.03

Dividend Yield

3.73%

Beta

0.6